GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » PB Ratio

Stoke Therapeutics (Stoke Therapeutics) PB Ratio : 5.27 (As of Jun. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-05), Stoke Therapeutics's share price is $15.90. Stoke Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $3.02. Hence, Stoke Therapeutics's PB Ratio of today is 5.27.

The historical rank and industry rank for Stoke Therapeutics's PB Ratio or its related term are showing as below:

STOK' s PB Ratio Range Over the Past 10 Years
Min: 0.86   Med: 2.01   Max: 5.26
Current: 5.26

During the past 7 years, Stoke Therapeutics's highest PB Ratio was 5.26. The lowest was 0.86. And the median was 2.01.

STOK's PB Ratio is ranked worse than
77.79% of 1310 companies
in the Biotechnology industry
Industry Median: 2.535 vs STOK: 5.26

During the past 12 months, Stoke Therapeutics's average Book Value Per Share Growth Rate was -37.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -23.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -3.90% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Stoke Therapeutics was 19.40% per year. The lowest was -23.70% per year. And the median was -11.80% per year.

Back to Basics: PB Ratio


Stoke Therapeutics PB Ratio Historical Data

The historical data trend for Stoke Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics PB Ratio Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 4.15 7.92 4.07 1.97 1.51

Stoke Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 2.47 1.01 1.51 4.47

Competitive Comparison of Stoke Therapeutics's PB Ratio

For the Biotechnology subindustry, Stoke Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stoke Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Stoke Therapeutics's PB Ratio falls into.



Stoke Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Stoke Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=15.90/3.018
=5.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Stoke Therapeutics  (NAS:STOK) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Stoke Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Stoke Therapeutics (Stoke Therapeutics) Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
Executives
Barry Ticho officer: Chief Medical Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jonathan Allan officer: General Counsel & Corp Sec C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Huw M. Nash officer: COO & CBO C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Atp Life Science Ventures, L.p. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Skorpios Trust 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau officer: EVP Research & Preclinical Dev C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin director 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Stephen J Tulipano officer: CFO C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Arthur Tzianabos director C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kaye Edward M. Md director, officer: CEO 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011

Stoke Therapeutics (Stoke Therapeutics) Headlines

From GuruFocus